Cancer is often driven by dysregulation of gene expression, which can be due to mutations in transcription factors or their binding sites. Identifying these key regulators and understanding their network of target genes can provide insights into the mechanisms driving cancer progression. iRegulon helps in pinpointing these critical TFs and their downstream effects, facilitating the discovery of novel biomarkers and therapeutic targets.